Search results
Results from the WOW.Com Content Network
More studies are needed, but long-term semaglutide use appears to be safe. A 2022 study — funded by Novo Nordisk, the manufacturer of Ozempic and Wegovy — found that taking semaglutide for two ...
Semaglutide is an anti-diabetic medication used for the treatment of type 2 diabetes and an anti-obesity medication used for long-term weight management. [23] [24] [25] It is a peptide similar to the hormone glucagon-like peptide-1 (GLP-1), modified with a side chain. [26] [27] It can be administered by subcutaneous injection or taken orally.
Often, the recommended treatment is a combination of lifestyle changes such as increasing exercise and healthy eating, along with medications to help control the BG levels in the long term. [2] In addition to management of the diabetes, patients are recommended to have routine follow up with specialist to manage possible common complications ...
Due to shorter duration of studies, this review did not allow for long-term positive or negative effects to be assessed. [27] Exenatide (also Exendin-4, marketed as Byetta) is the first GLP-1 agonist approved for the treatment of type 2 diabetes. Exenatide is not an analogue of GLP but rather a GLP agonist.
More research is needed on Ozempic long-term side effects. Some severe side effects with long-term consequences may include pancreatitis, acute kidney injury, gallstones, gallbladder disease ...
Metformin is a prescription medication used to treat high blood sugar in those with type 2 diabetes who are resistant to the effects of insulin. It’s in a class of drugs known as biguanides ...
GLP-1 agonists were initially developed for type 2 diabetes. [5] The 2022 American Diabetes Association (ADA) standards of medical care in diabetes include GLP-1 agonists or SGLT2 inhibitors as a first-line pharmacological therapy for type 2 diabetes in patients who have or are at high risk for atherosclerotic cardiovascular disease or heart failure.
Saroglitazar is indicated for the treatment of diabetic dyslipidemia and hypertriglyceridemia with type 2 diabetes mellitus not controlled by statin therapy. In clinical studies, saroglitazar has demonstrated reduction of triglycerides (TG), LDL cholesterol , VLDL cholesterol, non-HDL cholesterol and an increase in HDL cholesterol a ...